📇 Rhumatologue · LE MANS · (72) · Libéral

MME CYRILLE BACHELET-DUPEROU

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
77.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LE MANS (72)LibéralRPPS 10002137940

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR CYRILLE BACHELET-DUPEROU
2 AVENUE D'HAOUZA, 72100 LE MANS
☎ 0982294246Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis

Gastroenterology · 2019

📚 76 citations🎯 RCR 3.04Top 16% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

British journal of cancer · 2021

📚 52 citations🎯 RCR 2.81Top 18% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background CirCe01 trial aimed to assess the clinical utility of circulating tumour cell (CTC)-based monitoring in metastatic breast cancer (MBC) patients beyond the third line of chemotherapy (LC). Methods CirCe01 was a prospective, multicentre, randomised trial (NCT01349842) that included patients with MBC after two systemic LC. Patients with ≥5 CTC/7.5 mL (CellSearch®) were randomised between the CTC-driven and the standard arm. In the CTC arm, changes in CTC count were assessed at the first cycle of each LC; patients in whom CTC levels predicted early tumour progression had to switch to a subsequent LC. Results Greater than or equal to 5 CTC/7.5 mL were observed in N = 101/204 patients. In the CTC arm (N = 51), 43 (83%) and 18 (44%) patients completed CTC monitoring in the third and fourth lines, respectively, and 18 (42%) and 11 (61%) of these patients, respectively, had no CTC response. Thirteen (72%) and 5 (46%) of these patients underwent early switch to the next LC. Overall survival was not different between the two arms (hazard ratio = 0.95, 95% confidence interval = [0.6;1.4], p = 0.8). In subgroup analyses, patients with no CTC response who switched chemotherapy experienced longer survival than patients who did not. Conclusions Due to the limited accrual and compliance, this trial failed to demonstrate the clinical utility of CTC monitoring. Clinical Trial Registration NCT, NCT01349842, https://clinicaltrials.gov/ct2/show/NCT01349842, registered 9 May 2011.

Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study

Journal of the American College of Cardiology · 2020

📚 52 citations🎯 RCR 2.68Top 19% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME CYRILLE BACHELET-DUPEROU

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (32) — classées par pathologie

Transversal10

Essai clinique4

Case report / série3

Épidémiologie & registres3

Lupus3

Génétique2

Pédiatrie2

Qualité de vie / PROMs2

Corticothérapie1

Économie santé1

Pharmacovigilance1

Revue générale1

SAPL1

Vascularites des gros vaisseaux1

Partager cette fiche